SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Biotechnology Cancer Cures
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who started this subject9/24/2000 12:58:58 PM
From: PL Wilson   of 226
 
Kidney Cancer Experiment Appears Promising
By DENISE GRADY:September 19, 2000
In a report last week in The New England Journal of Medicine, Mr. Sirmans was Patient No. 19, one of the first 19 people to receive the experimental treatment, a transplant of cancer-fighting cells from the immune system of a brother or sister. All the patients had advanced kidney cancer that had spread to other organs and did not respond to conventional treatments. Few were expected to last more than a year.

In eight, the treatment did not work, and they died of cancer. Two died of complications from the treatment.

But nine, all treated more than a year ago, are still alive, including four in whom all signs of cancer have disappeared. One of those four was treated almost three years ago. In three of the five others still living, tumors shrank by more than half.

nytimes.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News